Skip to content

Postoperative Pain Therapy With Hydromorphone Using TCI-PCA

Phase 4 Study of Postoperative Pain Therapy With Hydromorphone Using Patient-Controlled Target-Controlled Infusion (TCI-PCA) vs. Patient-Controlled Analgesia (PCA) After Elective Cardiac Surgery

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02035709
Acronym
TCI-PCA
Enrollment
50
Registered
2014-01-14
Start date
2013-12-31
Completion date
2015-04-30
Last updated
2015-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain

Keywords

Therapy

Brief summary

Treatment of postoperative pain with hydromorphone (a strong analgesic) using patient-controlled analgesia with target concentrations in blood compared to conventional patient-controlled analgesia after planed cardiac surgery

Interventions

DRUGHydromorphone

Hydromorphone is given by PCA or TCI-PCA. The TCI-PCA System steer the hydromorphone infusion pump to achieve plasma concentrations of hydromorphone in predefined increasing steps on patient request and in predefined decreasing steps on lack of patient request within predefined plasma concentration range, lock times and infusion speed.

Sponsors

German Federal Ministry of Education and Research
CollaboratorOTHER_GOV
University of Erlangen-Nürnberg Medical School
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
40 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

* Written informed consent * Age between 40 and 85 years, both genders * Scheduled for elective cardiac surgery involving thoracotomy and subsequent ICU stay

Exclusion criteria

* Administration of other analgesics or sedatives, if not administered in stable dosage for at least 14 days or if not used for premedication and surgery * Administration of hydromorphone in the period between screening and surgery * Severe hepatic or renal impairment in medical history * BMI ≥35 kg/m² * ASA ≥4

Design outcomes

Primary

MeasureTime frameDescription
Hydromorphone Plasma ConcentrationsDay 0 (Visit 2 on day of surgery): -1, 3, 30, 90, 91, 93, 95, 97, 100 min after start of hydromorphone infusion but before extubation; one sample each hour for the following 17 hours after extubationPredictive accuracy of the Erlanger pharmacokinetic model of hydromorphone administered via TCI, TCI-PCA and conventional PCA during the early postoperative stage

Secondary

MeasureTime frameDescription
Numerical Rating ScoreDay 0 (Visit 2 on day of surgery): -1, 3, 30, 90, 91, 93, 95, 97, 100 min after start of hydromorphone infusion but before extubation; one sample each hour for the following 17 hours after extubationComparison between hydromorphone TCI-PCA and conventional hydromorphone PCA during the early postoperative stage regarding analgetic efficiency

Other

MeasureTime frameDescription
Amount of Hydromorphone AdministeredDay 1 (Visit 3 on first day after surgery)Comparison between hydromorphone TCI-PCA and conventional hydromorphone PCA during the early postoperative stage regarding the amount of hydromorphone administered

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 11, 2026